Hanaoka Kenjiro, Lubag Angelo Josue M, Castillo-Muzquiz Aminta, Kodadek Thomas, Sherry A Dean
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390-9185, USA.
Magn Reson Imaging. 2008 Jun;26(5):608-17. doi: 10.1016/j.mri.2007.11.002. Epub 2008 Jan 30.
Simple low molecular weight (MW) chelates of Gd(3+) such as those currently used in clinical MRI are considered too insensitive for most molecular imaging applications. Here, we evaluated the detection limit (DL) of a molecularly targeted low MW Gd(3+)-based T(1) agent in a model where the receptor concentration was precisely known. The data demonstrate that receptors clustered together to form a microdomain of high local concentration can be imaged successfully even when the bulk concentration of the receptor is quite low. A GdDO3A-peptide identified by phage display to target the anti-FLAG antibody was synthesized, purified and characterized. T(1-)weighted MR images were compared with the agent bound to antibody in bulk solution and with the agent bound to the antibody localized on agarose beads. Fluorescence competition binding assays show that the agent has a high binding affinity (K(D)=150 nM) for the antibody, while the fully bound relaxivity of the GdDO3A-peptide/anti-FLAG antibody in solution was a relatively modest 17 mM(-1) s(-1). The agent/antibody complex was MR silent at concentrations below approximately 9 microM but was detectable down to 4 microM bulk concentrations when presented to antibody clustered together on the surface of agarose beads. These results provided an estimate of the DLs for other T(1)-based agents with higher fully bound relaxivities or multimeric structures bound to clustered receptor molecules. The results demonstrate that the sensitivity of molecularly targeted contrast agents depends on the local microdomain concentration of the target protein and the molecular relaxivity of the bound complex. A model is presented, which predicts that for a molecularly targeted agent consisting of a single Gd(3+) complex with bound relaxivity of 100 mM(-1) s(-1) or, more reasonably, four tethered Gd(3+) complexes each having a bound relaxivity of 25 mM(-1) s(-1), the DL of a protein microdomain is approximately 690 nM at 9.4 T. These experimental and extrapolated DLs are both well below current literature estimates and suggests that detection of low MW molecularly targeted T(1) agents is not an unrealistic goal.
简单的低分子量(MW)钆(Gd(3+))螯合物,如目前临床磁共振成像(MRI)中使用的那些,被认为对大多数分子成像应用来说灵敏度不够。在此,我们在一个受体浓度精确已知的模型中评估了一种基于低分子量Gd(3+)的分子靶向T(1)剂的检测限(DL)。数据表明,即使受体的总体浓度相当低,聚集在一起形成高局部浓度微区的受体也能成功成像。合成、纯化并表征了一种通过噬菌体展示鉴定的靶向抗FLAG抗体的GdDO3A - 肽。将T(1)加权磁共振图像与该剂在大量溶液中与抗体结合的情况以及与该剂与固定在琼脂糖珠上的抗体结合的情况进行了比较。荧光竞争结合试验表明,该剂对抗体具有高结合亲和力(K(D)=150 nM),而溶液中GdDO3A - 肽/抗FLAG抗体的完全结合弛豫率相对适中,为17 mM(-1) s(-1)。当该剂/抗体复合物以低于约9 microM的浓度存在时磁共振信号沉默,但当它与聚集在琼脂糖珠表面的抗体结合时,在低至4 microM的总体浓度下仍可检测到。这些结果为其他具有更高完全结合弛豫率或与聚集受体分子结合的多聚体结构的基于T(1)的剂的检测限提供了估计。结果表明,分子靶向造影剂的灵敏度取决于靶蛋白的局部微区浓度和结合复合物的分子弛豫率。提出了一个模型,该模型预测,对于由单个结合弛豫率为100 mM(-1) s(-1)的Gd(3+)复合物组成的分子靶向剂,或者更合理地说,对于四个每个结合弛豫率为[25 mM(-1) s(-1)]的连接Gd(3+)复合物组成的分子靶向剂,在9.4 T时蛋白质微区的检测限约为690 nM。这些实验和外推的检测限均远低于当前文献估计值,表明检测低分子量分子靶向T(1)剂并非不切实际的目标。